Usage: PLUVICTO is indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibition and taxane-based chemotherapy.
Usage: POSLUMA is a PET imaging agent used to detect PSMA-positive lesions in men with prostate cancer who have suspected metastasis before initial definitive therapy, or suspected recurrence based on elevated PSA levels.